Publications by authors named "Kirk Culotta"

Claim this Profile
T
Toxicity Evaluation of a Novel Magnetic Resonance Imaging Marker, CoCl2-N-Acetylcysteine, in Rats.
Li Wang, Mihai Gagea, Karen Martirosyan, Mary Johansen, Timothy Madden, Kirk S Culotta

J Toxicol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
Siqing Fu, Kirk S Culotta, Gerald S Falchook, David S Hong, Alan L Myers

Cancer Chemother Pharmacol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical and chemical stability of proflavine contrast agent solutions for early detection of oral cancer.
Jitesh D Kawedia, Yan-Ping Zhang, Alan L Myers, Rebecca R Richards-Kortum, Mark A Kramer, Kirk S Culotta

J Oncol Pharm Pract· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
Fu Siqing, Kirk S Culotta, Gerald S Falchook, David S Hong, Alan L Myers

Cancer Chemother Pharmacol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.
Salah-Eddine Lamhamedi-Cherradi, Brian A Menegaz, Vandhana Ramamoorthy, Ramani A Aiyer, Rebecca L Maywald, Kirk S Culotta

Mol Cancer Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Naval Daver, Yanis Boumber, Hagop Kantarjian, Farhad Ravandi, Jorge Cortes, Kirk S Culotta

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Ana M Gonzalez-Angulo, Ian Krop, Argun Akcakanat, Huiqin Chen, Shuying Liu, Kirk S Culotta

J Natl Cancer Inst· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.
Apostolia M Tsimberidou, Rabih Said, Kirk Culotta, Ignacio Wistuba, Jaroslav Jelinek

Clin Epigenetics· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
David S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, Gerald S Falchook, Aung Naing, Kirk S Culotta

Cancer· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.
YanPing Zhang, Jitesh D Kawedia, Alan L Myers, Chelsey M McIntyre, Peter M Anderson, Kirk S Culotta

J Oncol Pharm Pract· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
Michael A Davies, Patricia S Fox, Nicholas E Papadopoulos, Agop Y Bedikian, Wen-Jen Hwu, Kirk S Culotta

Clin Cancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity.
Siqing Fu, Aung Naing, Stacy L Moulder, Kirk S Culotta, David C Madoff

Mol Cancer Ther· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Busulfan and metronidazole: an often forgotten but significant drug interaction.
Alison M Gulbis, Kirk S Culotta, Roy B Jones, Borje S Andersson

Ann Pharmacother· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
Heather D Brooks, Bonnie S Glisson, B Nebiyou Bekele, Faye M Johnson, Lawrence E Ginsberg, Kirk S Culotta

Cancer· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.
Anne S Tsao, Diane Liu, Jack Martin, Xi-ming Tang, J Jack Lee, Kirk S Culotta

Cancer Prev Res (Phila)· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell CD3 receptor zeta (TCRzeta)-chain expression in children with idiopathic nephrotic syndrome.
Diego H Aviles, Matti V Vehaskari, Kirk S Culotta, Jennifer Manning, Augusto C Ochoa

Pediatr Nephrol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment.
Arnold H Zea, Kirk S Culotta, Juzar Ali, Carol Mason, Hae-Joon Park

J Infect Dis· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes.
Arnold H Zea, Paulo C Rodriguez, Kirk S Culotta, Claudia P Hernandez, Joanna DeSalvo

Cell Immunol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.
Paulo C Rodriguez, Arnold H Zea, Joanna DeSalvo, Kirk S Culotta, Jovanny Zabaleta

J Immunol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of T cell receptor CD3zeta chain expression by L-arginine.
Paulo C Rodriguez, Arnold H Zea, Kirk S Culotta, Jovanny Zabaleta, Juan B Ochoa

J Biol Chem· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis